Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Chantry

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Oncotarget|June 7, 2018
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samplesDavid K Edwards V, David Tyler Sweeney, Hibery Ho, et al.
Journal of Medicinal Chemistry|August 11, 2012
Potent and highly selective benzimidazole inhibitors of PI3-kinase deltaJeremy M Murray, Zachary K Sweeney, Bryan K Chan, et al.
Cancer Research|June 12, 2016
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid LeukemiaLohith Bachegowda, Kerry Morrone, Shannon L Winski, et al.
Bioorganic & Medicinal Chemistry Letters|June 8, 2012
Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelfDaniel P Sutherlin, Stewart Baker, Angelina Bisconte, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Oncotarget|June 7, 2018
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samplesDavid K Edwards V, David Tyler Sweeney, Hibery Ho, et al.
Journal of Medicinal Chemistry|August 11, 2012
Potent and highly selective benzimidazole inhibitors of PI3-kinase deltaJeremy M Murray, Zachary K Sweeney, Bryan K Chan, et al.
Cancer Research|June 12, 2016
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid LeukemiaLohith Bachegowda, Kerry Morrone, Shannon L Winski, et al.
Bioorganic & Medicinal Chemistry Letters|June 8, 2012
Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelfDaniel P Sutherlin, Stewart Baker, Angelina Bisconte, et al.
Pageof 2